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Inflammation and oxidative stress are two faces of one coin in end stage renal disease patients
(ESRD) on maintenance hemodialysis. Their interconnection induces anemia complicated with
erythropoietin hyporesponsiveness. The biochemical bases behind the resistance to erythropoi-
etin therapy with frequent hemoglobinemia, oxidative stress and iron status have not been fully
understood. Here two equal groups (40 patients each) of responders and non-responders to
recombinant human erythropoietin therapy (higher than 300 IU/kg/wk of epoetin) were inves-
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Vitamin Ctigated. Hematological and biochemical analyses of collected blood and serum samples were
performed along with serum electrophoretic protein footprinting. The leukocytic DNA frag-
mentation was used to evaluate the degree of oxidative insult. The good responders showed
lower erythrocyte malondialdehyde (E-MDA) level and less DNA fragmentation of circulating
leukocytes than poor responders with elevated hemoglobin, albumin, A/G ratio, total iron, and
ferritin levels. Contrariwise, lower erythrocyte superoxide dismutase (E-SOD) and catalase
activities in EPO poor responder group were noticed. Neither other serum constituents nor elec-
trophoretic protein pattern showed any difference between the two groups. There were higher
levels of inflammatory markers, interleukin-6 (IL6) and C-reactive protein (CRP) in EPO poor
responder than good responder. The negative correlations between Hb and both IL6 and CRP
levels in the present data remotely indicate a positive correlation between inflammatory markers
and severity of anemia. A direct correlation between Hb and antioxidant enzymes (E-SOD and
catalase) was noticed, while inverse correlation with E-MDA was recorded. The study proved
that oral supplementation of vitamin C to ESRD patients might mitigate the previously elevated
serum MDA level in these patients.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Anemia is a risk factor for progression of chronic kidney dis-
ease (CKD) to end stage renal disease (ESRD) [1]. The degree
of anemia in CKD patients tends to be parallel with altered
kidney function manifested by considerable patients’ variabil-
ity [2]. Insufficient erythropoietin (EPO) production is the pri-
mary cause of renal anemia during ESRD, due to partially or
completely depleted or injured specialized peritubular cells
responsible for its production [3]. Anemia was secondary pro-
moted by other factors, including active blood loss, haemo-
globinopathies, aluminum overload, hypothyroidism [4].
Impaired erythropoiesis also contributes to anemia as a result
of poor response to EPO with reduced proliferative activity of
erythroid precursors in bone marrow and erythrophagocytosis
[5]. Further oxidative damage of RBCs membrane in chronic
hemodialysis (HD) patients that decreases erythrocytes life
span could exaggerate renal anemia [6]. The condition is con-
sequently associated with a decreased quality of life [7] and
cardiovascular complications [8]. That requires intense hospi-
talization [9]. Such anemia should be corrected by erythro-
poiesis stimulating agents (ESAs) therapy that slows down the
progression ofCKD [1]. Although themajority ofCKDpatients
respond adequately to ESAs, 10% of these patients showed
marked resistance to recombinant human erythropoietin
(rhEPO) therapy [10]. Resistance to ESAs has been associated
with an increased risk of cardiovascular events in CKD patients
[11] with increased mortality and morbidity rates [12].
Oxidative stress is a constituent of the inflammatory mecha-
nisms that contributes to anemia of ESRD patients. The degree
of oxidative stress is closely correlated with the inflammatory
status of ESRD patients undergoing HD [13]. The mechanism
includes the depletion of redox capacity with membrane struc-
tural deformity and shortened life span of erythrocytes. This
consequently elevates the production of hepcidin; a hormone
that inhibits both intestinal absorption of iron andmobilization
of iron stores by binding to ferroportin on the cell membrane
with diminished expression of iron-transport protein transferrin
and induction of erythropoietin resistance [14].
A close association between high levels of inflammatory
markers and ESAs resistance in CKD patients has been
reported [15]. Elevated circulating interleukin 6 (IL6) –as one
of inflammatory cytokines intimately correlated with poorresponse to EPO treatment in ESRD on HD. These inflamma-
tory cytokines can impair bone marrow function and
significantly alter iron metabolism. This increased state of
pro-inflammatory cytokine activity in CKD adversely restrains
erythroid progenitor cell production that advances to hypore-
sponsiveness to ESAs and poor treatment outcomes [16].
Another gold standard as a micro-inflammatory marker in
HD is the C-reactive protein (CRP) that predicts mortality
after adjustment for other risk factors. Its level significantly
increases comparable with other acute-phase proteins, making
it a convenient clinical evaluator [17]. Furthermore, Costa
et al., [18] reported that CKD patients on HD present with
high levels of inflammatory markers, namely CRP, IL6, tumor
necrosis factor-alpha (TNF-a), and interferon-c and with
lower serum levels of albumin.
Maintenance of balanced redox state is an important mod-
ulator in immune system homeostasis [19]. Imbalanced cellular
redox state evokes cellular free radicals flooding with elevated
inflammatory mediators that amplify the cascade of vicious
cycle of generation of reactive oxygen species (ROS). Either
chronic or acute production of free radicals contributes to lipid
peroxidation, protein denaturation, and deoxyribonucleic acid
remodeling [20]. Long periods of HD treatment are linked to
DNA damage due to increased oxidative stress [21].
Vitamin C (ascorbic acid), on the other hand, is a potent
water-soluble antioxidant in biological fluids by scavenging
ROS (O2
 and OH) and reactive nitrogen species by forming
semi-dehydroascorbic acid that mitigates oxidative damage of
important biomolecules. It is an effective antioxidant against
lipid peroxidation. Vitamin C deficiency in CKD patients on
HD may be secondary to dietary restriction of fresh fruits
and vegetables, to avoid hyperkalemia and loss of the vitamin
when receiving dialysis [22]. Therefore, supplementation of
ascorbic acid is essential, because the need for vitamin C
increases in HD patients [23].
The current study aimed to better clarify the mechanisms of
resistance to rhEPO therapy and the influence of inflammatory
cytokines on erythropoietin production, and understand
the interplay of the multiple factors involved in the pathogen-
esis of the anemia of chronic disease. Moreover, studying
biochemical changes is associated with hyporesponsiveness to
rhEPO therapy in HD patients with particular interest on
oxidative status in the form of cell membrane deterioration
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as well as the disturbances in antioxidant enzymatic activity of
superoxide dismutase and catalase on erythropoietin response.
The study also addressed the antioxidant role of Vitamin C in
alleviation of the hazard potentially induced by elevated ROS
during progression of CKD.
Patients and methods
Patients and study design
A group of 80 ESRD patients (30 males and 50 females)
undergo regular HD; their ages ranged from 39 to 55 years;
duration of HD 7.59 ± 2.3 years, treated with rhEPO, was
selected from more than 170 HD surveyed outpatients at
nephrology clinic – Maadi Armed Forces Hospital.
All patients were routinely dialyzed three times a week, 4 h
per session, using high flux polysulfone capillary dialyzers
(Fresenius Medical Care, Bad Homburg, Germany) and
bicarbonate dialysate (Na+: 103 mmol/L; K+: 2.0 mmol/L;
Ca2+: 1.75 mmol/L; Mg2+: 0.5 mmol/L; Cl: 109.5 mmol/L;
HCO3
: 35 mmol/L). The blood flow rate ranged from 80 to
200 mL/min, according to body weight; dialysis flow was
500 mL/min with heparin anticoagulant. Mean dialysis
dose Kt/V was 1.89. All patients were supported with
L-Carnitine and B-complex supplementation after each
session of HD.
The ESRD patients included 40 poor responders
(Hb < 11 g/dL and rhEPO dose > 300 IU/kg/week) and 40
good responders to rhEPO therapy (Hb > 11 g/dL and rhEPO
dose < 300 IU/kg/week). Classification of the patients into
poor or good responder was performed in accordance with
the European Best Practice Guidelines [24], which defines resis-
tance to rhEPO as a failure to achieve target hemoglobin levels
(between 11 and 12 g/dL) with maintained doses of rhEPO
higher than 300 IU/kg/week of epoetin (Eprex).
For studying the effect of antioxidant therapy on dialysis
patients, another group of 20 ESRD patients was included.
This group has been divided into 10 ESRD patients on HD
orally supplemented with 500 mg vitamin C, twice daily for
one month, according to a previous recommendation of Dei-
cher and Horl [23], and 10 ESRD on HD patients served as
control (without vitamin C supplementation).
Patients with recent blood transfusion, autoimmune dis-
ease, malignancy, hematological disorders, parathormone level
>250 pg/mL and acute or chronic infection before the begin-
ning of the study, as well as patients who were on supplemen-
tation with vitamin C and/or E during the 3 months before the
beginning of the study were excluded.
The written patients’ approval consents were taken and the
study followed the required Ethics Committee obligations stated
by Cairo University scientific research protocol for handling of
non-invasive samples (blood samples) from human subjects.
Blood sampling
Blood samples were taken twice from the HD patients, imme-
diately before (pre-HD) and after (post-HD) dialysis sessions
from arteriovenous fistulas, in vacutainer tubes with anticoag-
ulants (ethylene diamine tetra-acetic acid (EDTA), sodiumcitrate, and lithium heparin) and without anticoagulant for
obtaining serum samples.
Biochemical analysis
Serum samples were obtained after centrifugation (3000 rpm
for 10 min), and subjected to the measurement of biochemical
parameters including kidney function tests (blood urea, serum
creatinine, and uric acid), liver function tests (total bilirubin,
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), and alkaline phosphatase (ALP)), protein profile (total
proteins, albumin, globulin, and A/G ratio), lipids (total
cholesterol level, triglycerides), blood glucose level, total iron,
calcium, and phosphorus by Hitachi 917 (Hitachi Corp.,
Roche-Diagnostic, Mannheim, Germany), automatic clinical
chemistry analyzer using routine laboratory techniques and
available commercial kits (Roche-Diagnostic).
Blood electrolytes
Na+ and K+ were determined in serum samples by a direct
ion selective electrode method using Audicom 9101
(AC9101), an electrolyte analyzer (Horiba Medical, Audicom
Medical Instrument Co., Ltd. Jiangsu, China).
Osmolality test
Citrated plasma samples were used for determination of
plasma osmolality by measuring the freezing point depression,
using automatic cryoscopic osmometer (Osmomat 030,
Gonotec, Berlin, Germany).
Complete blood count (CBC)
EDTA-coated tubes were used for the CBC measurements,
including hemoglobin, hematocrit, leukocytes, mean cell vol-
ume and platelets using automatic cell counter (Sysmex
XP300, Hamburg, Germany).
Determination of serum ferritin level
An electrochemiluminescence immunoassay ‘‘ECLIA” tech-
nique was performed for detection of ferritin level in serum
samples by using Elecsys 2010 immunoassay analyser
(Roche-Diagnostic, Mannheim, Germany). Two monoclonal
mouse antibodies – M-4.184 and M-3.170 (available kit from
Roche-Diagnostic) were used to form the sandwich complex
in the assay.
Inflammatory markers
T-cell and monocyte function were assessed by measuring
proinflammatory cytokine secretion from the mononuclear
cells – IL-6 in serum, using commercially available enzyme
linked immunosorbent assay (ELISA) kits (Biosource, Diag-
nostic Corporation, USA). The plates were read at 450 nm
on a computerized automated VersaMax micro-plate ELISA
reader (Molecular Devices Inc., Sunnyvale, CA, USA).
Oxidative stress in erythropoietin hyporesponsiveness anemia at end stage renal disease 351CRP level assay
A quantitative determination of CRP level (mg/L) in serum
samples was assayed by a turbidometric immunoassay in
which a serum sample is mixed with latex beads coated with
anti-human CRP antibodies forming an insoluble aggregate,
using Indiko auto analyzer (IndikoTM Plus; Thermo-scientific,
North America).
Determination of erythrocyte malondialdehyde (E-MDA) in
hemolysate
For preparation of erythrocyte hemolysate, EDTA blood sam-
ple was centrifuged at 4000 rpm for 15 min and the plasma was
removed. The recovered erythrocytes were successively washed
with saline solution and lysed at room temperature incubation
in hypotonic double distilled water containing 5 mL/L Triton
X 100. This was followed by vigorous vortex mixing. The
membrane free hemolysate was obtained by centrifugation at
10,000 rpm for 5 min. Estimation of E-MDA was carried out
according to the procedure described by Albro et al. [25].
Two and half mL of 10% Trichloracetic acid (TCA) was added
to 0.5 mL hemolysate in a centrifuge tube, mixed well and kept
for 15 min in boiling water bath. The tubes were cooled under
tap water prior to addition of 1 mL of distilled water. After
good mixing, tubes were centrifuged at 4000 rpm for 10 min.
Two mL of filtered supernatant was mixed with 1 mL of thio-
barbituric acid (TBA) and the mixture was placed in boiling
water bath for 20 min. The optical density of the pre-cooled
mixture was measured by spectrophotometer (Model 752N,
Anjing Everich Medicare Co., Ltd. Jiangsu, China) at
532 nm against TBA blank. E-MDA concentration was
expressed as lmol/g Hb.
Determination of erythrocyte superoxide dismutase activity
(E-SOD)
The enzymatic activity of E-SOD in erythrocyte hemolysate
was assessed according to the method of Marklund and Mark-
lund [26]. Addition of 5 lL hemolysate to 25 lL pyrogallol
(24 mmol/L prepared in 10 mmol HCl) and the final volume
were adjusted to 3 mL using Tris HCl buffer (0.1 M, pH
7.8). The change in absorbance was recorded by spectropho-
tometer (Model 752N, Anjing Everich Medicare Co., Ltd.
Jiangsu, China) at 420 nm for 3 min. E-SOD activity was
expressed as U/mg Hb.
Preparation of purified leukocytes for ex vivo estimation of
catalase activity (CAT)
The leukocytes-rich buffy coat was separated from heparinized
blood samples by standard techniques using Ficoll-Hypaque
gradient density (density 1077 g/L), centrifugation at
1000 rpm for 30 min at 20 C (Pharmacia LKB, Uppsala, Swe-
den). Cells (peripheral blood mononuclear cells) were washed
in Hanks balanced salt solution (HBSS; Life Technologies
BRL, Life Technologies Ltd, Paisley, UK) (600g, 10 min,
and 4 C). Two additional washes with HBSS were performed
(200g, 10 min, and 4 C). As an indirect reflection of real
immune status an ex vivo leukocytic catalase activity was thenmeasured as a function of the rate of oxygen release using
Clark oxygen electrode unit (Rank Brothers, Cambridge,
UK) connected with chart recorder (Kipp and Zonen BD112
medical desk-top dual channel flatbed chart recorder, Hol-
land). Ten lg protein from previously purified leukocytes
was used to estimate their catalase activity. Taking normal
subjects as control, the catalase activity was arbitrary mea-
sured by the developing slope formed by the oxygen release
in unit time (rate of oxygen release from hydrogen peroxide
via catalase action). The hydrogen peroxide substrate ade-
quately added in access (>> above 25 mM H2O2 which is
its catalase Km value) to drive the reaction into zero order
kinetics. The zero order kinetics is a state at which the rate
of catalytic conversion is mainly dependent on the enzyme
activity under investigation. The oxygen concentration base-
line was previously estimated by previous consumption of buf-
fer ambient O2 via equilibration of buffer in the measurement
unit with 0.5 nmol of sodium hydrosulfite (Sigma–Aldrich).
DNA fragmentation assay as an oxidative stress marker
EDTA blood samples were used for isolation of DNA. The
assay was basically performed after salting out extraction fol-
lowing the method described by Aljanabi and Martinez [27].
Briefly the proteins and other cellular contaminants were
salted out from saturated 5 M NaCl salt solution. The DNA
was then precipitated by ice-cold absolute isopropanol. The
purified genomic DNA was resolved by agarose gel elec-
trophoresis (1.5% agarose in TAE buffer with 5 V/cm migra-
tion voltage) using horizontal minigel electrophoresis unit
(BIO-Rad laboratories Inc., CA, USA). The ethidium bromide
pre-stained resolved DNA was visualized by UV detector
(Bench top Visible/UV transilluminator, Thermo-scientific,
North America). The intensity of DNA was measured via
Gel Pro Analyzer free Software using 100 bp DNA ladder
marker (Vivantis Technologies, Selangor, Malaysia).
Protein foot printing
Protein pattern analysis of serum samples was performed
according to the procedure of Laemmli [29], using denatured
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–PAGE). Prestained wide range molecular weight marker
(BIO-RAD Laboratories, Hercules, CA, USA) was used.
Antioxidant effect of vitamin C
The plasma vitamin C level was determined colorimetrically,
following the method of Kyaw [30] using available kit (Biodi-
agnostic, Giza, Egypt). The method was based on mixing of
2, 6 dichlorophenol indophenol (DCPIP) with plasma samples
in acidic medium. DCPIP dye reduced to a colorless leuco base
while ascorbate is oxidized to dehydroascorbate. This redox
reaction was measured by spectrophotometer (Model 752N,
Anjing Everich Medicare Co., Ltd., Jiangsu, China) and ascor-
bate concentration was expressed as mg/L.
Determination of lipid peroxidation product in serum
A colorimetric method for quantitative analysis of lipid perox-
ide in serum samples was used according to the procedure
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sodium sulfate solution in order to avoid the interference of
sialic acid. TBA reacts with MDA in acidic medium at temper-
ature of 95 C for 30 min to form thiobarbituric acid reactive
product. By adding n-butyl alcohol, the resulting chromogen
was extracted and the absorbance of the organic phase was
measured spectrophotometrically at 530 nm (Model 752N,
Anjing Everich Medicare Co., Ltd. Jiangsu, China). Serum
MDA concentration was expressed as nmol/L, using standard
curve.
Statistical analysis
Statistical analysis was performed using Statistical Package for
Social Science (SPSS; SPSS version 16.0 for Microsoft Win-
dows, Inc. Chicago, IL, USA). Power analysis of several
biomarkers has been determined in patients with CKD, and
resulted in N= 40 with power = 0.8 and alpha = 0.05 (data
not shown). Independent t-test was used to compare the results
between groups and paired t-test was used for comparison
between pre and post dialysis within group. All values are
expressed as mean ± SE. A P-value less than 0.05 was consid-
ered statistically significant, except serum ferritin level, which
is non-normally distributed variable. Thus, the P-value is
based on nonparametric test of Mann–Whitney U Test. Spear-
man’s rank correlations were performed to explore relation-
ships among the blood variables.
Results
The rhEPO therapy in HD group showed non-significant dif-
ference in most of biochemical parameters measured e.g. urea,
creatinine, uric acid, total bilirubin level, as well as ALP and
AST activity between EPO poor responders and good respon-
ders Table 1. A significant elevation was observed in ALT
activity in good responder patients when compared with poor
responder ones but still, however, within the reference ranges.
Both serum albumin and A/G ratio (Table 1 and Fig. 1) were
significantly elevated in EPO good responders than poor
responders group (3.99 ± 0.076 vs. 3.77 ± 0.07) and (1.43
± 0.08 vs. 1.16 ± 0.05), respectively. In respect of circulating
bioenergetic reserve parameters neither blood glucose nor did
lipids (cholesterol and triglycerides) show any significant vari-
ation between groups. More importantly there was non-
significant difference noticed between both groups in plasma
osmolality, electrolytes, as well as calcium and phosphorus
levels.
Logically, serum iron level recorded highly significant ele-
vation in EPO good responders than poor responders (84.29
± 7.12 vs. 50.91 ± 5.12; P< 0.001) as presented in Table 1
with highly significant decline in Hb levels (8.96 ± 0.24 vs.
12.18 ± 0.11) with P-value < 0.001. Also, lower serum ferritin
levels (ng/mL) 409.81 (56–727.2) were noticed in EPO poor
responder group.
Table 2 and Fig. 2a displayed the significant increase in
serum IL6 levels (ng/mL) in ESRD (uremic) patients above
the normal ranges (<9 ng/mL) in poor responders to EPO
than good responders pre HD, while post HD level showed
non-significant rise in poor responder patients when compared
with good responders. These data also declared a slight non-
significant elevation in IL6 levels after HD than pre HD levelsin poor responder group (24.06 ± 3.01 vs. 19.01 ± 2.08),
while a significant elevation was recorded in good responders
after HD as compared with pre HD levels (18.38 ± 2.20 vs.
11.45 ± 1.13). A significant elevation of CRP levels was
observed in EPO poor responder than good responder ESRD
patients (Table 2 and Fig. 2b) before and after dialysis (14.83
± 1.33 vs. 4.20 ± 0.61 and 30.00 ± 2.17 vs. 16.75 ± 1.54,
respectively).
In Table 3 a highly significant rise was observed in E-MDA
levels (lmoL/g Hb) in EPO poor responders than in good
responders (42.60 ± 2.19 vs. 31.7 ± 0.96; P< 0.001), while
significant decline in SOD activity (U/g Hb) was recorded in
EPO poor responders than in good responder group (1.62
± 0.25 vs. 2.62 ± 0.15; P< 0.05). In the same way, Fig. 3 dis-
played falling of catalase activity in leukocytes of both ESRD
groups on HD when compared with control subjects.
Table 4 recorded a significantly direct correlation between
Hb and each of iron, ferritin, albumin levels, and E-SOD activ-
ity (0.655**, 0.327*, 0.355**, 0.678**), respectively, while inverse
correlation was noticed between Hb and each of oxidative
stress (E-MDA) and inflammatory markers (IL6 and CRP)
(0.468*, 0.297*, and 0.376**), respectively. In the same
way, serum iron also negatively correlated with IL6 and
CRP (0.307*, 0.336*), respectively, along with positively
correlated with E-SOD and ferritin (0.564**, 0.562**),
respectively.
Fig. 4 represented agarose gel analysis of DNA fragmenta-
tion extracted from plasma and leukocytes of EPO poor and
good responder ESRD patients pre and post HD. DNA frag-
mentation was clearer in poor responder patients especially
post HD (as in lane 3), as DNA fragments showed dense lower
smearing (more fragmentation) when compared with good
responder group post HD (lane 6) observed with less dense
lower smearing (less fragmentation). The appearance of upper
smearing in lanes 3 and 6 after dialysis that disappeared from
lanes 7 and 8 prior to it might confirm the stressful condition
induced by dialysis.
Protein foot printing of serum from control subject and
ESRD patients (poor and good responders to EPO) displayed
in Fig. 5 showed minimal variations in protein expression
between the studied groups. There is no obvious difference
in protein banding between poor responders and good respon-
ders except slight increase in concentration of the heavy molec-
ular weight proteins (>130 kDa) in poor responders that is
more obvious in lane 8.
The data displayed in Table 5 recorded a significant
decrease in plasma vitamin C level (mg/L) after HD in both
vitamin C supplemented and unsupplemented groups
(P< 0.001; % of change: 62% and 75%), respectively
when compared with pre HD levels. However, vitamin C sup-
plemented patients (Fig. 6a) showed a significant higher vita-
min C values than unsupplemented groups before and after
HD session (53.278 ± 4.825 vs. 30.94 ± 2.186) and (20.288
± 3.688 vs. 7.782 ± 1.549), respectively. Table 5 and Fig. 6b
also recorded a highly significant increase in serum MDA level
(nmol/L) after HD in non-vitamin C supplemented ESRD
group than pre HD level (P< 0.001, % of change: 52%).
Studying the effect of vitamin C supplementation on lipid per-
oxidation product in serum, a significantly lowering effect of
vitamin C supplementation was pronounced in serum MDA
level of vitamin C supplemented patients after HD when com-
pared with un-supplemented group (5.7 ± 0.377 vs. 8.38
Table 1 Biochemical parameters of EPO poor responder and good responder ESRD patients.
Parameters Poor responders Good responders P-value
Urea (mg/dL) 140.13 ± 5.91 143.70 ± 5.84 0.669
Creatinine (mg/dL) 10.28 ± 0.41 11.22 ± 0.53 0.172
Uric acid (mg/dL) 6.87 ± 0.24 7.01 ± 0.32 0.735
ALP (U/L) 139.96 ± 23.44 154.54 ± 21.50 0.739
AST (U/L) 17.83 ± 1.45 22.24 ± 3.46 0.250
ALT (U/L) 15.58 ± 2.05 24.58 ± 3.53 0.034
Total bilirubin (mg/dL) 0.48 ± 0.02 0.50 ± 0.03 0.646
Total proteins (g/dL) 7.11 ± 0.11 6.97 ± 0.18 0.531
Albumin (g/dL) 3.77 ± 0.07 3.99 ± 0.07 0.048
Globulin (g/dL) 3.33 ± 0.10 2.98 ± 0.17 0.092
A/G ratio 1.16 ± 0.05 1.43 ± 0.08 0.010
Cholesterol (mg/dL) 176.25 ± 8.13 191.17 ± 12.70 0.329
Triglycerides (mg/dL) 151.67 ± 13.74 213.83 ± 25.81 0.101
Blood glucose (mg/dL) 94.95 ± 3.94 99.45 ± 4.58 0.461
Total iron (lg/dL) 50.91 ± 5.12 84.29 ± 7.12 <0.001
Calcium (mg/dL) 8.70 ± 0.21 8.36 ± 0.15 0.213
Phosphorus (mg/dL) 5.41 ± 0.18 5.24 ± 0.24 0.584
Sodium (mmol/L) 137.70 ± 1.29 140.50 ± 1.31 0.138
Potassium (mmol/L) 5.83 ± 0.10 5.75 ± 0.13 0.608
Plasma osmolality (mos moL/kg) 232.64 ± 21.28 247.5 ± 16.02 0.582
Hb (g/dL) 8.96 ± 0.244 12.18 ± 0.11 <0.001
Ferritin (ng/mL) 409.81* (56–727.2) 672.25* (414–1220) 0.020
All values represented as Mean ± S.E (N= 40). NS = no significant differences at P> 0.05. S = significant difference between groups at
P< 0.05. HS = highly significant difference between groups at P< 0.001.
* Nonparametric values (50–75th).
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Table 2 Pre and post HD levels of inflammatory marker (IL6
and CRP) in serum of EPO poor responder and good
responder ESRD patients.
Poor responders Good responders P-value
IL6 (ng/ml)
Pre HD 19.01 ± 2.08 11.45 ± 1.13 0.039
Post HD 24.06 ± 3.01 18.38 ± 2.20 0.301
P-value 0.387 0.049
CRP (mg/l)
Pre HD 14.83 ± 1.33 4.20 ± 0.61 0.020
Post HD 30.00 ± 2.17 16.75 ± 1.54 0.049
P-value 0.048 0.014
All values are represented as Mean ± S.E (N= 40). NS = no
significant differences at P> 0.05. S = significant difference
between groups at P< 0.05.
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Table 3 Pre HD levels of E-MDA and E-SOD of EPO poor and good responder patients.
Parameters Poor responders Good responders P-value
E-MDA (lmol/g Hb) 42.60 ± 2.19 31.72 ± 0.96 0.001
E-SOD (U/g Hb) 1.62 ± 0.25 2.62 ± 0.15 0.004
All values are represented as Mean ± S.E (N= 40). S = significant difference between groups at P< 0.05. HS = highly significant difference
between groups at P< 0.001.
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Fig. 3 Catalase activity.
Table 4 Interrelations between parameters of EPO poor responder
Parameters Correlation with Hb P-value
Iron 0.655** <0.001
Ferritin 0.327* 0.023
IL6 0.297* 0.041
CRP 0.376** 0.009
Albumin 0.355** 0.013
E-MDA 0.468* 0.037
E-SOD 0.678** 0.001
* Correlation is significant at the 0.05 level (2-tailed), N= 40.
** Correlation is significant at the 0.01 level (2-tailed), N= 40.
M 1 2 3 4 5
Fig. 4 Electrophoretic pattern of DNA fragmentation assay. Agaro
ladder. Lane (1): DNA extracted from leukocytes of control subject sho
subject. Lane (3): DNA extracted from leukocytes of EPO poor respon
responders’ pre HD. Lane (5): DNA extracted from plasma of EPO poo
EPO good responders post HD. Lane (7): DNA extracted from leuko
from leukocytes of EPO good responders pre HD. Lane (9): DNA ext
DNA extracted from plasma of EPO good responders post HD.
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both groups before HD. In respect of serum iron levels, vita-
min C supplemented group recorded lower values than unsup-
plemented group, and thus reaching significant difference in
post HD levels (107.6 ± 8.60 vs. 166.7 ± 15.18).
Discussion
Alterations of the immune system in ESRD constitute a com-
plex issue. Here the results confirm the rise in IL-6 levels-as
pro-inflammatory cytokines-above the normal levels found in
HD patients. Accumulation of proinflammatory cytokines as
a consequence of decreased renal elimination and/or increasedand good responder ESRD patients.
Parameters Inter correlations P-value
CRP & IL6 0.331* 0.022
Iron & ferritin 0.562** <0.001
Iron & IL6 0.307* 0.034
Iron & CRP 0.336* 0.020
Iron & E-SOD 0.564** 0.010
E-MDA & E-SOD 0.394 0.096
6 7 8 9 10
se gel electrophoresis of DNA fragmentation. Lane (M): 100 Bp
wed intact DNA. Lane (2): DNA extracted from plasma of control
ders post HD. Lane (4): DNA extracted from plasma of EPO good
r responders pre HD. Lane (6): DNA extracted from leukocytes of
cytes of EPO poor responders pre HD. Lane (8): DNA extracted
racted from plasma of EPO poor responders post HD. Lane (10):
Fig. 5 Protein foot printing of serum from control and ESRD patients (poor and good responders to EPO). Lane (M): Marker (7 ll).
Lanes (1): serum from control subject. Lane (2,4,6,8): serum from EPO poor responder HD patient. Lane (3,5,7,9): serum from EPO
good responder HD patient.
Table 5 Pre and post HD levels of plasma vitamin C, serum MDA, and serum total iron of vitamin C supplemented and
unsupplemented ESRD patients.
Vitamin C unsupplemented Vitamin C supplemented P-value
Plasma vitamin C (mg/L)
Pre HD 30.94 ± 2.18 53.27 ± 4.82 <0.001
Post HD 7.78 ± 1.54 20.28 ± 3.68 0.005
% of change 75 62
P-value <0.001 <0.001
Serum MDA (nmol/L)
Pre HD 3.99 ± 0.29 4.94 ± 0.51 0.122
Post HD 8.38 ± 0.68 5.7 ± 0.37 0.002
% of change 52 13
P-value <0.001 0.264
Total iron (lg/dL)
Pre HD 113.2 ± 10.63 89.11 ± 9.79 0.112
Post HD 166.7 ± 15.18 107.6 ± 8.60 0.003
% of change 32 17
P-value 0.009 0.189
All values are represented as Mean ± S.E. (N= 10). NS = no significant differences at P> 0.05. S = significant difference at P< 0.05.
HS = highly significant difference at P< 0.001.
0
10
20
30
40
50
60
70
pl
as
m
a 
vi
ta
m
in
 C
 le
ve
l (
m
g/
L)
Vitamin C unsupplemented Vitamin C supplemented
 pre HD
post HD
Fig. 6a Plasma Vitamin C levels in Vitamin C supplemented and
unsupplemented HD patients.
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following induction by uremic toxins and oxidative stress [31].
On the other hand, uremia is associated with immunosuppres-
sion due to the influence of the uremic milieu and a variety of
associated disorders exerted on immune-competent cells.
Pecoits-Filho et al. [32] also suggested that the level of proin-
flammatory cytokines in HD patients is higher than healthy
control as ESRD potentiates hypercytokinemia involving IL-6.
Many studies have linked a high level of proinflammatory
cytokines with poor outcome in renal patients. Eschbach [33]
revealed that chronic immune activation in ESRD patients
possibly caused by either contact of immune cells with dialysis
membranes or from repeated infection. These patients fre-
quently present deviated homeostasis of body iron with typical
anemia observed in chronic disease. Del Vecchio et al. [34] also
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Fig. 6b Serum MDA levels in Vitamin C supplemented and
unsupplemented HD patients.
356 S.K.M. Khalil et al.reported that cytokine-induced inflammation suppresses bone
marrow erythropoiesis in HD patients with possible aggrava-
tion of anemia.
Surprisingly, the level of IL6 showed serum persistent eleva-
tion even after hemodialysis regardless of EPO therapy. This
agreed with Massey and McPherson [35] finding that suggested
a diverse elimination kinetic behavior of IL-6 cytokines despite
its relative low molecular weight (26.5 kDa). Tarakc et al. [36]
stated that HD session does not change serum levels of IL-1,
IL-6, and TNF-a, underlining importance of the structural
characteristics of the molecules. Girndt et al. [37] also reported
unchanged serum IL-6, during HD concurrent with increased
clearance or membrane adsorption of these cytokines. The rel-
atively short half-lives (3–7 min) with potential rapid binding
of plasma cytokines cell surface receptors might imply stable
plasma concentration achieved by continuous high production
rate of IL-6.
The effect of immune dysfunction on the erythropoietin
response in ESRD patients on maintenance HD was displayed
in the present study by a significant rise in both IL-6 and CRP
levels in EPO poor responder than good responder patients pre
HD, with clear negative correlation between Hb concentra-
tions with both IL-6 level and CRP. The same observations
were previously noticed by Carrero et al. [38], who attributed
the higher serum levels of IL-6 that reflects CRP concentration
with lower Hb level in HD patients to quench the EPO therapy
response. Furthermore, the inverse correlation between CRP
and Hb indirectly correlates CRP with anemia in patients kept
on HD [39]. The recorded inverse correlation between CRP
and mean cell volume, mean corpuscular hemoglobin, and
serum iron in our investigation might support the notion of
Costa et al. [40] that chronic inflammation was intensified in
EPO non-responder patients with potential macrophages iron
trapping and consequent serum iron reduction.
In respect of iron status, a significant negative correlation
between IL-6 and serum iron levels parallel with positive cor-
relation between the later and ferritin levels explained the role
of IL-6 proinflammatory in induction of EPO resistance ane-
mia and direct inhibitory effect on erythroid progenitor cells
with possible disruption of iron metabolism due to hepcidin
up-regulation [41]. Hepcidin is a type II acute-phase protein
produced in the liver that has been proposed to be the central
regulator of iron metabolism. These findings consistent with
Nemeth et al. [42], who illustrated that proinflammatorycytokines, mainly IL-6, negatively affect iron metabolism by
stimulating the synthesis of hepcidin. Moreover, relation of
Hb levels with serum iron and serum ferritin demonstrated
the effect of these parameters on the incidence of anemia.
These relations were described by Weiss and Goodnough
[43] who stated that anemia of chronic disease is immune
driven.
Obviously, the highest ferritin level in EPO good responder
patients is in agreement with previous study [44].
Serum albumin, on the other hand, offers a predictor of
baseline Hb level in patients with chronic HD, since hypoalbu-
minemia is usually connected with suppressed erythropoiesis
[45] with considerably minor response to rhEPO in patients
with lower serum albumin levels. Therefore, it is not surpris-
ingly that the circulating albumin displayed a direct correlation
with Hb levels. Moreover, serum albumin has an antioxidant
activity through inhibition of erythrocyte membrane lipid per-
oxidation. Since there was a proved correlation between devi-
ated redox homeostasis and altered serum proteome [46], the
serum proteome foot-printing was compared among the two
groups. Unlike the previous finding [47], there was no major
variation seen in electrophoretic protein pattern between the
two groups.
Oxidative stress aggravates lipid peroxidation [48]. In
accord with our results, Zachara et al. [49] revealed that HD
induces oxidative stress with initiation of lipid peroxidation.
Focusing on ESAs therapy, the data support previous notion
of Ludat et al. [50] that EPO good responder patients recorded
lower MDA level than poor one with improved Hb status and
potential decrease in free radicals generation.
ESRD patients on HD are usually suffering from the inter-
action between dialysis membranes and their blood. Sosa et al.
[51] proved that this direct contact has to trigger the release of
oxygen free radicals and oxidizing agents, such as superoxide
anion, hydrogen peroxide, and myeloperoxidase. In turn, these
molecules contribute to the oxidation of various bio-polymers
e.g. lipids, proteins and nucleic acids. Thus, accelerated demise
of circulating erythrocytes, and shorten RBCs life span are the
core of next pathological consequences. Therefore, the
observed negative correlation between Hb level and lipid per-
oxidation marker (E-MDA) with positive correlation between
Hb and antioxidant activity presented by E-SOD, can be
established by this phenomena. Along with the predominant
DNA fragmentation – as an indicator of total genomic damage
noticed in our study, Stopper et al. [52] demonstrated a clear
relationship between renal failure and genomic damage in
HD patients. Likewise, Gonzalez et al. [53] indicated that this
damage is a sole convenient parameter of increased free radi-
cals production and imbalanced cellular redox homeostasis,
which potentially deteriorates metabolism. Superoxide dismu-
tase action is intra-cellularly augmented with catalase and
GSH-Pxs in quenching harmful effects induced by ROS [54].
Significant decline in both leukocytic catalase activity and ery-
throcyte SOD activity with higher MDA levels, was recorded
in the study. These results were supported by Farzaneh et al.
[55] who suggested that long duration of dialysis initiates
decrease in erythrocytic antioxidant activity with subsequent
rise in the rate of lipid peroxidation.
Serum MDA level is the global marker of polyunsaturated
fatty acid peroxidation with twofold increase above the basal
level after dialysis in HD patients [56]. Our study proved the
antioxidant effect of vitamin C – as oral supplementation –
Oxidative stress in erythropoietin hyporesponsiveness anemia at end stage renal disease 357in reducing the post dialysis serum MDA level (32%) than that
in unsupplemented group.
Since vitamin C has a regulatory role in declining serum
iron level via facilitating iron absorption and utilization with
EPO effect augmentation [57], this investigation explains the
virtue of orally-supplemented ascorbic acid as more conve-
nient, less invasive, and shortly administrated way than the
widely accepted parenteral route. Thus, we can deduce that
the goal of reducing the HD-induced oxidative damage can
be achieved by oral vitamin C supplement. In contrary to
our finding however, Fumeron et al. [58] recognized that nor-
malization of plasma total vitamin C forms by oral supplemen-
tation did not correct the level of previously identified
oxidative stress and/or inflammatory markers.
Conclusions
The results have conveyed an excessive linkage between inflam-
matory status and oxidative imbalance induced by chronic
dialysis process in EPO hyporesponsiveness HD patients. In
order to improve responsiveness to rhEPO therapy oral sup-
plementation with vitamin C was prescribed and monitored
before and after HD. The work proved that antioxidant vita-
min C supplementation – in low oral dosing – may enhance
antioxidant defense mechanisms with mitigation of oxidative
damages and thus reducing the requirement of high rhEPO
dosing.
Limitations of the study
There were some limitations to the present study. For example,
we did specify the patients who had vitamin C deficiency, and
measure their plasma vitamin C levels before the beginning of
the study, which burden the ability to generalize the findings.
In addition, relatively few number of patients was under study.
Thus, it is recommended to carry out studies with larger sam-
ple sizes, and longer term of vitamin C supplementation.
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